Bluebird bio, Inc.
BLUE
Κατάταξη σε μετοχές
#15560
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery,... bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
Τιμή μετοχής
$4.97
Τελευταίος συγχρονισμός: 2025-06-02
Κεφαλαιοποίηση
$318.62M
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
-38.03%
Χώρα
US
Εμπόριο Bluebird bio, Inc. (BLUE)
Κατηγορία
Healthcare
Ιστορικό τιμής μετοχής για την Bluebird bio, Inc. (BLUE)
Υψηλότερη τιμή κλεισίματος: $8.24 στις 2025-01-01
Χαμηλότερη τιμή κλεισίματος: $1.93K στις 2018-01-01
Χαμηλότερη τιμή κλεισίματος: $1.93K στις 2018-01-01
Ιστορικό τιμής μετοχής της Bluebird bio, Inc. από 2018 έως 2026
Ετήσια απόδοση τιμής μετοχής
| Έτος | Απόδοση |
|---|---|
| 2025 | -0.01% |
| 2024 | -86.21% |
| 2023 | -60.75% |
| 2022 | -23.07% |
| 2021 | -59.15% |
| 2020 | -57.22% |
| 2019 | -15.48% |
| 2018 | 0.00% |
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Τιμή μετοχής | Μεταβολή 1Έτ% | Χώρα |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
